We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Big Canadian Pharma Taps Sparta for Lifecycle Management

Big Canadian Pharma Taps Sparta for Lifecycle Management

September 12, 2006

Apotex, the largest Canadian-owned pharmaceutical company, has selected Sparta Systems’ TrackWise web-based software platform to capture and track all regulatory information required for new products and the entire span of product lifecycle management.

Apotex produces more than 300 generic pharmaceuticals in more than 4,000 dosages. The company’s pharmaceuticals are in virtually every pharmacy and healthcare facility in Canada, and its products are exported to more than 115 countries around the world.

The TrackWise system will provide Apotex an electronic, integrated solution for product lifecycle management activities required to meet the needs of an ever-expanding global market. The system will be used to manage submissions, amendments, change notices, periodic safety reports, commitments and other regulatory activities, Sparta officials told PIR Sept. 11.

Apotex sought a configurable, integrated, web-based and expandable solution to deal with the regulatory complexities that result from producing its generic pharmaceuticals.

A key point for Apotex was that the system it chose had to be configurable, requiring no source code customization or changes to the database schema. The company was also looking for a solution that could adapt and grow to their other business based on the architecture and licensing structure.

To ensure edata accuracy, Apotex also required that the system be able to capture maintenance processes, have triggers in place to review data changes, and automatically drive enforcement of field level verification and format control.

Apotex also demanded a system to monitor and track all required regulatory affairs management information, including esubmissions and action items.

In making its selection, Apotex sought a system that met all 21 CFR Part 11 requirements, including esignature and audit trails.

Apotex scored products based on their abilities to address the company’s needs. In addition, Apotex sought vendor references as well as feedback from industry analysts. It then brought in a few finalists for product demonstrations.

Sparta’s TrackWise is designed to allow organizations to implement secure, robust and expandable tracking solutions to manage regulatory compliance data, activities and work processes. With its ability to centralize quality processes into a single, integrated system, TrackWise aims to help organizations gain efficiencies and achieve compliance by integrating related events and actions, automating workflow, and facilitating trending and reporting across regulatory activities.

KEYWORDS Technology

    Upcoming Events

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Potential Penalties Force BMS to Sign Drug Price Negotiation Agreement With CMS

    • Despite AdComm Endorsement, neffy Nasal Spray Alternate for EpiPen Gets CRL

    • Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

    • Reports Allege Philips Withheld Evidence of Ventilator Malfunctions for 11 Years

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing